New opportunities for RGD-engineered metal nanoparticles in cancer.

Qin, Wei; Chandra, Jyoti; Abourehab, Mohammed A S; Gupta, Neelima; Chen, Zhe-Sheng; Kesharwani, Prashant; Cao, Hui-Ling

Qin, Wei; Chandra, Jyoti; Abourehab, Mohammed A S; Gupta, Neelima; Chen, Zhe-Sheng; Kesharwani, Prashant; Cao, Hui-Ling.

Afiliação

Qin W; Xi'an Key Laboratory of Basic and Translation of Cardiovascular Metabolic Disease, College of Pharmacy, Xi'an Medical University, Xi'an, 710021, China.
Chandra J; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India.
Abourehab MAS; Department of Pharmaceutics, College of Pharmacy, Umm Al-Qura University, Makkah, 21955, Saudi Arabia.
Gupta N; Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, Madhya Pradesh, 470003, India.
Chen ZS; Institute for Biotechnology, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, 11439, USA.
Kesharwani P; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India. prashantdops@gmail.com.
Cao HL; Center for Transdisciplinary Research, Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical science, Chennai, India. prashantdops@gmail.com.

Mol Cancer ; 22(1): 87, 2023 05 25.

Article em En | MEDLINE | ID: mdl-37226188

Assuntos

Nanopartículas Metálicas; Neoplasias; Humanos; Sequência de Aminoácidos; Glicina; Oligopeptídeos

Palavras-chave

Cancer imaging; Drug targeting; Integrin; Metal nanoparticles; RGD; cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nanopartículas Metálicas / Neoplasias Limite: Humans Idioma: En Revista: Mol Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google